Parkinson's Disease Therapeutics Pipeline Program
The Michael J. Fox Foundation's Pipeline Program funds translational research to advance new Parkinson’s disease therapies, emphasizing projects ready for pre-clinical or clinical development milestones.
Funder: Michael J. Fox Foundation for Parkinson's Research
Due Dates: June 25, 2026 | July 10, 2026 (Pre-proposal) | August 20, 2026 | Projected future cycles available; see below for all dates
Funding Amounts: Typical awards range from $250,000 (targeted projects) up to $2M (multi-stage programs) for 1–3 years; scope and budget negotiated if invited to full proposal.
Summary: Supports translational pre-clinical and clinical research to accelerate new Parkinson’s disease therapies, with emphasis on projects ready for development milestones.
Key Information: Pre-proposals are required and accepted on a rolling basis; only industry or academic–industry partnership applications are eligible.
Description
The Parkinson's Disease Therapeutics Pipeline Program is the flagship funding initiative of the Michael J. Fox Foundation for Parkinson's Research (MJFF), designed to accelerate the development of new therapies for Parkinson’s disease. The program seeks projects that generate meaningful, decision-informing evidence to advance therapies through pre-clinical and clinical development. Emphasis is placed on disease-modifying or symptomatic interventions and the integration of biomarker tools to inform development milestones.
The program is structured for rapid engagement: pre-proposals are accepted on a rolling basis, and selected applicants are invited to submit full proposals in one of several annual review cycles. MJFF encourages applications from industry, and from academic teams partnered with industry, to foster clear pathways to commercialization and broader patient impact.
